Emerging techniques to treat corneal neovascularisation

Eye

Volumn 26, Issue 1, 2012, Pages 2-12

  Menzel Severing, J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

cornea; gene therapy; translational research; vascular development

Indexed keywords

ADENOVIRUS VECTOR; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANGIOPOIETIN; ANTISENSE OLIGONUCLEOTIDE; BEVACIZUMAB; CORTICOSTEROID; CYCLOSPORIN A; ENDOSTATIN; FIBROBLAST GROWTH FACTOR; INSULIN RECEPTOR SUBSTRATE 1; PIGMENT EPITHELIUM DERIVED FACTOR; PLATELET DERIVED GROWTH FACTOR; PREDNISOLONE; SMALL INTERFERING RNA; THROMBOSPONDIN; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; BLEEDING; CAUTERIZATION; CORNEA DISEASE; CORNEA EROSION; CORNEA NEOVASCULARIZATION; CORNEA THINNING; DRUG EFFICACY; DRUG SAFETY; ELECTROPORATION; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; GENE SILENCING; GENE TRANSFER; HEALING IMPAIRMENT; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN SECRETION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIRAL GENE THERAPY;

EID: 84855829740     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2011.246     Document Type: Review

References (119)

1. Lee P, Wang CC, Adamis AP. Ocular neovascularization: an epidemiologic review. Surv Ophthalmol 1998; 43: 245-269. (Pubitemid 28558273)
2. Michaelson IC. The mode of development of the vascular system of the retina. With some observations on its significance for certain retinal diseases. Trans Ophthalmol Soc UK 1948; 68: 137.
3. Campbell FW, Michaelson IC. Blood-vessel formation in the cornea. Br J Ophthalmol 1949; 33: 248-255.
4. Pardanaud L, Yassine F, Dieterlen-Lievre F. Relationship between vasculogenesis, angiogenesis and haemopoiesis during avian ontogeny. Development 1989; 105: 473-485. (Pubitemid 19093155)
5. Risau W. Mechanisms of angiogenesis. Nature 1997; 386: 671-674. (Pubitemid 27193480)
6. Choi K, Kennedy M, Kazarov A, Papadimitriou JC, Keller G. A common precursor for hematopoietic and endothelial cells. Development 1998; 125: 725-732. (Pubitemid 28108096)
7. Hiraoka N, Allen E, Apel IJ, Gyetko MR, Weiss SJ. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell 1998; 95: 365-377. (Pubitemid 28507325)
8. Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 2003; 161: 1163-1177. (Pubitemid 36870177)
9. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407: 242-248.
10. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
11. Dorrell M, Uusitalo-Jarvinen H, Aguilar E, Friedlander M. Ocular neovascularization: basic mechanisms and therapeutic advances. Surv Ophthalmol 2007; 52: S3-S19. (Pubitemid 46107520)
12. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-364. (Pubitemid 26272076)
13. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000; 6: 389-395. (Pubitemid 30208155)
14. Burger PC, Chandler DB, Klintworth GK. Corneal neovascularization as studied by scanning electron microscopy of vascular casts. Lab Invest 1983; 48: 169-180. (Pubitemid 13144377)
15. Beebe DC Maintaining transparency: a review of the developmental physiology and pathophysiology of two avascular tissues. Semin Cell Dev Biol 2008; 19: 125-133. (Pubitemid 351258368)
16. Pufe T, Petersen WJ, Miosge N, Goldring MB, Mentlein R, Varoga DJ et al. Endostatin/collagen XVIII-an inhibitor of angiogenesis-is expressed in cartilage and fibrocartilage. Matrix Biol 2004; 23: 267-276. (Pubitemid 39298976)
17. Yoshioka M, Yuasa S, Matsumura K, Kimura K, Shiomi T, Kimura N et al. Chondromodulin-I maintains cardiac valvular function by preventing angiogenesis. Nat Med 2006; 12: 1151-1159. (Pubitemid 44527350)
18. Goldberg MF. Persistent fetal vasculature (PFV): an integrated interpretation of signs and symptoms associated with persistent hyperplastic primary vitreous (PHPV). LIV Edward Jackson Memorial Lecture. Am J Ophthalmol 1997; 124: 587-626. (Pubitemid 27469239)
19. Ellenberg D, Azar DT, Hallak JA, Tobaigy F, Han KY, Jain S et al. Novel aspects of corneal angiogenic and lymphangiogenic privilege. Prog Retin Eye Res 2010; 29: 208-248.
20. Gabison E, Chang J-H, Hernández-Quintela E, Javier J, Lu PC, Ye H et al. Anti-angiogenic role of angiostatin during corneal wound healing. Exp Eye Res 2004; 78: 579-589. (Pubitemid 38183337)
21. Chang JH, Gabison EE, Kato T, Azar DT. Corneal neovascularization. Curr Opin Ophthalmol 2001; 12: 242-249. (Pubitemid 32751680)
22. Azar DT. Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity vasculogenesis, and wound healing (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 2006; 104: 264-302. (Pubitemid 46495064)
23. Cursiefen C, Colin J, Dana R, Diaz-Llopis M, Faraj LA, Garcia-Delpech S et al. Consensus statement on indications for anti-angiogenic therapy in the management of corneal diseases associated with neovascularisation: outcome of an expert roundtable. Br J Ophthalmol 2011; e-pub ahead of print 28 June 2011; doi:10.1136/bjo.2011.204701.
24. Qazi Y, Maddula S, Ambati BK. Mediators of ocular angiogenesis. J Genet 2009; 88: 495-515.
25. Bachmann B, Taylor RS, Cursiefen C. Corneal neovascularization as a risk factor for graft failure and rejection after keratoplasty: an evidence-based meta-analysis. Ophthalmology 2010; 117: 1300-1305.e7.
26. Cursiefen C, Chen L, Dana MR, Streilein JW. Corneal lymphangiogenesis: evidence, mechanisms, and implications for corneal transplant immunology. Cornea 2003; 22: 273-281. (Pubitemid 36359171)
27. Dietrich T, Bock F, Yuen D, Hos D, Bachmann BO, Zahn G et al. Cutting edge: lymphatic vessels, not blood vessels, primarily mediate immune rejections after transplantation. J Immunol 2010; 184: 535-539.
28. Rajappa M, Saxena P, Kaur J. Ocular angiogenesis: mechanisms and recent advances in therapy Adv Clin Chem 2010; 50: 103-121.
29. Millauer B, Wizigmann-Voos S, Schnürch H, Martinez R, Møller NP, Risau W et al. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993; 72: 835-846. (Pubitemid 23110226)
30. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306-1309. (Pubitemid 20066716)
31. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996; 380: 439-442. (Pubitemid 26102720)
32. Terman BI, Dougher-Vermazen M, Carrion ME, Dimitrov D, Armellino DC, Gospodarowicz D et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 1992; 187: 1579-1586.
33. Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, Hartnett ME. Vascular endothelial growth factor in eye disease. Prog Retin Eye Res 2008; 27: 331-371.
34. Kaipainen A, Korhonen J, Pajusola K, Aprelikova O, Persico MG, Terman BI et al. The related FLT4, FLT1, and KDR receptor tyrosine kinases show distinct expression patterns in human fetal endothelial cells. J Exp Med 1993; 178: 2077-2088. (Pubitemid 23344864)
35. Binétruy-Tournaire R, Demangel C, Malavaud B, Vassy R, Rouyre S, Kraemer M et al. Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. EMBO J 2000; 19: 1525-1533. (Pubitemid 30182160)
36. Amano S, Rohan R, Kuroki M, Tolentino M, Adamis AP. Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci 1998; 39: 18-22. (Pubitemid 28040457)
37. Bock F, Onderka J, Dietrich T, Bachmann B, Pytowski B, Cursiefen C. Blockade of VEGFR3-signalling specifically inhibits lymphangiogenesis in inflammatory corneal neovascularisation. Graefes Arch Clin Exp Ophthalmol 2008; 246: 115-119. (Pubitemid 350162691)
38. Cheng T, Cao W, Wen R, Steinberg RH, LaVail MM. Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Müller cells. Invest Ophthalmol Vis Sci 1998; 39: 581-591. (Pubitemid 28110692)
39. Behzadian MA, Wang XL, Al-Shabrawey M, Shabrawey M, Caldwell RB. Effects of hypoxia on glial cell expression of angiogenesis-regulating factors VEGF and TGF-beta. Glia 1998; 24: 216-225. (Pubitemid 28403999)
40. Kvanta A, Sarman S, Fagerholm P, Seregard S, Steen B. Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization. Exp Eye Res 2000; 70: 419-428. (Pubitemid 30658885)
41. Mastyugin V, Mosaed S, Bonazzi A, Dunn MW, Schwartzman ML. Corneal epithelial VEGF and cytochrome P450 4B1 expression in a rabbit model of closed eye contact lens wear. Curr Eye Res 2001; 23: 1-10. (Pubitemid 34494008)
42. Terranova VP, DiFlorio R, Lyall RM, Hic S, Friesel R, Maciag T. Human endothelial cells are chemotactic to endothelial cell growth factor and heparin. J Cell Biol 1985; 101: 2330-2334. (Pubitemid 16169965)
43. Gospodarowicz D, Abraham JA, Schilling J. Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells. Proc Natl Acad Sci USA 1989; 86: 7311-7315. (Pubitemid 19254450)
44. Soubrane G, Jerdan J, Karpouzas I, Fayein NA, Glaser B, Coscas G et al. Binding of basic fibroblast growth factor to normal and neovascularized rabbit cornea. Invest Ophthalmol Vis Sci 1990; 31: 323-333. (Pubitemid 20072698)
45. Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005; 16: 159-178. (Pubitemid 40616114)
46. Murakami M, Simons M. Fibroblast growth factor regulation of neovascularization. Curr Opin Hematol 2008; 15: 215-220. (Pubitemid 351507574)
47. Onguchi T, Han KY, Chang J-H, Azar DT. Membrane type-1 matrix metalloproteinase potentiates basic fibroblast growth factor-induced corneal neovascularization. Am J Pathol 2009; 174: 1564-1571.
48. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000; 2: 737-744.
49. Lindahl P, Johansson BR, Levéen P, Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997; 277: 242-245. (Pubitemid 27446080)
50. Abramsson A, Lindblom P, Betsholtz C. Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J Clin Invest 2003; 112: 1142-1151. (Pubitemid 38056291)
51. Glade Bender J, Cooney EM, Kandel JJ, Yamashiro DJ. Vascular remodeling and clinical resistance to antiangiogenic cancer therapy Drug Resist Updat 2004; 7: 289-300. (Pubitemid 39469101)
52. Pérez-Santonja JJ, Campos-Mollo E, Lledó-Riquelme M, Javaloy J, Alió JL. Inhibition of corneal neovascularization by topical bevacizumab (anti-VEGF) and Sunitinib (Anti-VEGF and Anti-PDGF) in an animal model. Am J Ophthalmol 2010; 150: 519-528.e1.
53. Visconti RP, Richardson CD, Sato TN. Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF). Proc Natl Acad Sci USA 2002; 99: 8219-8224. (Pubitemid 34651033)
54. Coxon A, Bready J, Min H, Kaufman S, Leal J, Yu D et al. Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2- neutralizing peptibody Mol Cancer Ther 2010; 9: 2641-2651.
55. Ambati BK, Nozaki M, Singh N, Takeda A, Jani PD, Suthar T et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature 2006; 443: 993-997. (Pubitemid 44646176)
56. Ambati BK, Patterson E, Jani P, Jenkins C, Higgins E, Singh N et al. Soluble vascular endothelial growth factor receptor-1 contributes to the corneal antiangiogenic barrier. Br J Ophthalmol 2007; 91: 505-508. (Pubitemid 46623686)
57. Cursiefen C, Chen L, Saint-Geniez M, Hamrah P, Jin Y, Rashid S et al. Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. Proc Natl Acad Sci USA 2006; 103: 11405-11410. (Pubitemid 44156530)
58. Makino Y, Cao R, Svensson K, Bertilsson G, Asman M, Tanaka H et al. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 2001; 414: 550-554. (Pubitemid 33131538)
59. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999; 285: 245-248. (Pubitemid 29329995)
60. Karakousis PC, John SK, Behling KC, Surace EM, Smith JE, Hendrickson A et al. Localization of pigment epithelium derived factor (PEDF) in developing and adult human ocular tissues. Mol Vis 2001; 7: 154-163. (Pubitemid 36153665)
61. Abdiu O, Van Setten G Antiangiogenic activity in tears: presence of pigment-epithelium-derived factor. New insights and preliminary results. Ophthalmic Res 2008; 40: 16-18. (Pubitemid 350308298)
62. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-328. (Pubitemid 24324921)
63. Twining SS, Wilson PM, Ngamkitidechakul C. Extrahepatic synthesis of plasminogen in the human cornea is up-regulated by interleukins-1alpha and -1beta. Biochem J 1999; 339( Pt 3): 705-712. (Pubitemid 29243535)
64. Ambati BK, Joussen AM, Ambati J, Moromizato Y, Guha C, Javaherian K et al. Angiostatin inhibits and regresses corneal neovascularization. Arch Ophthalmol 2002; 120: 1063-1068. (Pubitemid 34856074)
65. Tonini T, Rossi F, Claudio PP. Molecular basis of angiogenesis and cancer. Oncogene 2003; 22: 6549-6556. (Pubitemid 37372334)
66. Lin H-C, Chang J-H, Jain S, Gabison EE, Kure T, Kato T et al. Matrilysin cleavage of corneal collagen type XVIII NC1 domain and generation of a 28-kDa fragment. Invest Ophthalmol Vis Sci 2001; 42: 2517-2524. (Pubitemid 32954857)
67. O'Reilly MS, Wiederschain D, Stetler-Stevenson WG, Folkman J, Moses MA. Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J Biol Chem 1999; 274: 29568-29571.
68. Armstrong LC, Bornstein P. Thrombospondins 1 and 2 function as inhibitors of angiogenesis. Matrix Biol 2003; 22: 63-71. (Pubitemid 36444508)
69. Cursiefen C, Masli S, Ng TF, Dana MR, Bornstein P, Lawler J et al. Roles of thrombospondin-1 and -2 in regulating corneal and iris angiogenesis. Invest Ophthalmol Vis Sci 2004; 45: 1117-1124. (Pubitemid 38869016)
70. Volpert OV, Tolsma SS, Pellerin S, Feige JJ, Chen H, Mosher DF et al. Inhibition of angiogenesis by thrombospondin-2. Biochem Biophys Res Commun 1995; 217: 326-332. (Pubitemid 26006308)
71. Oshima Y, Oshima S, Nambu H, Kachi S, Takahashi K, Umeda N et al. Different effects of angiopoietin-2 in different vascular beds: new vessels are most sensitive. FASEB J 2005; 19: 963-965. (Pubitemid 40827718)
72. Lin C-T, Hu F-R, Kuo K-T, Chen YM, Chu HS, Lin YH et al. The different effects of early and late bevacizumab (Avastin) injection on inhibiting corneal neovascularization and conjunctivalization in rabbit limbal insufficiency Invest Ophthalmol Vis Sci 2010; 51: 6277-6285.
73. Pillai CT, Dua HS, Hossain P. Fine needle diathermy occlusion of corneal vessels. Invest Ophthalmol Vis Sci 2000; 41: 2148-2153. (Pubitemid 30450986)
74. Cursiefen C, Hofmann-Rummelt C, Küchle M, Schlötzer-Schrehardt U. Pericyte recruitment in human corneal angiogenesis: an ultrastructural study with clinicopathological correlation. Br J Ophthalmol 2003; 87: 101-106. (Pubitemid 36071788)
75. Regenfuss B, Bock F, Parthasarathy A, Cursiefen C. Corneal (lymph)angiogenesis-from bedside to bench and back: a tribute to Judah Folkman. Lymphat Res Biol 2008; 6: 191-201.
76. Hos D, Saban DR, Bock F, Regenfuss B, Onderka J, Masli S et al. Suppression of inflammatory corneal lymphangiogenesis by application of topical corticosteroids. Arch Ophthalmol 2011; 129(4): 445-452.
77. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
78. Kenyon BM, Voest EE, Chen CC, Flynn E, Folkman J, D'Amato RJ et al. A model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci 1996; 37: 1625-1632. (Pubitemid 26271414)
79. Campochiaro PA. Ocular versus extraocular neovascularization: mirror images or vague resemblances. Invest Ophthalmol Vis Sci 2006; 47: 462-474. (Pubitemid 46772885)
80. Campochiaro PA. Potential applications for RNAi to probe pathogenesis and develop new treatments for ocular disorders. Gene Ther 2006; 13: 559-562.
81. Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherrer A, Liao F et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002; 8: 831-840.
82. Auerbach R, Akhtar N, Lewis RL, Shinners BL. Angiogenesis assays: problems and pitfalls. Cancer Metastasis Rev 2000; 19: 167-172. (Pubitemid 32004706)
83. Kim SW, Ha BJ, Kim EK, Tchah H, Kim TI. The effect of topical bevacizumab on corneal neovascularization. Ophthalmology 2008; 115: e33-e38.
84. Yu CQ, Zhang M, Matis KI, Kim C, Rosenblatt MI. Vascular endothelial growth factor mediates corneal nerve repair. Invest Ophthalmol Vis Sci 2008; 49: 3870-3878.
85. Cursiefen C, Bock F, Horn FK, Kruse FE, Seitz B, Borderie V et al. GS-101 antisense oligonucleotide eye drops inhibit corneal neovascularization: interim results of a randomized phase II trial. Ophthalmology 2009; 116: 1630-1637.
86. Andrieu-Soler C, Berdugo M, Doat M, Courtois Y, BenEzra D, Behar-Cohen F Downregulation of IRS-1 expression causes inhibition of corneal angiogenesis. Invest Ophthalmol Vis Sci 2005; 46: 4072-4078. (Pubitemid 44264606)
87. Bock F, Regenfuß B, Cursiefen C. [Antiangiogenic therapy at the ocular surface: When, what and why?]. Ophthalmologe 2011; 108: 230-236.
88. Singh N, Macnamara E, Rashid S, Ambati J, Kontos CD, Higgins E et al. Systemic soluble Tie2 expression inhibits and regresses corneal neovascularization. Biochem Biophys Res Commun 2005; 332: 194-199. (Pubitemid 40719473)
89. Murthy RC, McFarland TJ, Yoken J, Chen S, Barone C, Burke D et al. Corneal transduction to inhibit angiogenesis and graft failure. Invest Ophthalmol Vis Sci 2003; 44: 1837-1842. (Pubitemid 36520270)
90. Lai CM, Brankov M, Zaknich T, Lai YK, Shen WY, Constable IJ et al. Inhibition of angiogenesis by adenovirus-mediated sFlt-1 expression in a rat model of corneal neovascularization. Hum Gene Ther 2001; 12: 1299-1310. (Pubitemid 32681844)
91. Lai YK, Shen WY, Brankov M, Lai CM, Constable IJ, Rakoczy PE. Potential long-term inhibition of ocular neovascularisation by recombinant adeno-associated virus-mediated secretion gene therapy Gene Ther 2002; 9: 804-813. (Pubitemid 34679308)
92. Singh N, Amin S, Richter E, Rashid S, Scoglietti V, Jani PD et al. Flt-1 intraceptors inhibit hypoxia-induced VEGF expression in vitro and corneal neovascularization in vivo. Invest Ophthalmol Vis Sci 2005; 46: 1647-1652. (Pubitemid 44843599)
93. Jani PD, Singh N, Jenkins C, Raghava S, Mo Y, Amin S et al. Nanoparticles sustain expression of Flt intraceptors in the cornea and inhibit injury-induced corneal angiogenesis. Invest Ophthalmol Vis Sci 2007; 48: 2030-2036. (Pubitemid 351261271)
94. Yu W-Z, Li X-X, She H-C, He PY, Dong JQ, Rui M et al. Gene transfer of kringle 5 of plasminogen by electroporation inhibits corneal neovascularization. Ophthalmic Res 2003; 35: 239-246. (Pubitemid 36980792)
95. Reich SJ, Fosnot J, Kuroki A, Tang W, Yang X, Maguire AM et al. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis 2003; 9: 210-216. (Pubitemid 38097589)
96. Kim B, Tang Q, Biswas PS, Xu J, Schiffelers RM, Xie FYet al. Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis. Am J Pathol 2004; 165: 2177-2185. (Pubitemid 39578394)
97. Stechschulte SU, Joussen AM, von Recum HA, Poulaki V, Moromizato Y, Yuan J et al. Rapid ocular angiogenic control via naked DNA delivery to cornea. Invest Ophthalmol Vis Sci 2001; 42: 1975-1979. (Pubitemid 32726027)
98. Kuo C-N, Yang L-C, Wu P-C, Kuo HK, Kuo CJ, Tai MH. Dehydrated form of plasmid expressing basic fibroblast growth factor-polyethylenimine complex is a novel and accurate method for gene transfer to the cornea. Curr Eye Res 2005; 30: 1015-1024. (Pubitemid 43154695)
99. Mezentsev A, Mastyugin V, Seta F, Ashkar S, Kemp R, Reddy DS et al. Transfection of cytochrome P4504B1 into the cornea increases angiogenic activity of the limbal vessels. J Pharmacol Exp Ther 2005; 315: 42-50. (Pubitemid 41380496)
100. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007; 6: 273-286. (Pubitemid 46505878)
101. Auerbach R, Arensman R, Kubai L, Folkman J. Tumor-induced angiogenesis: lack of inhibition by irradiation. Int J Cancer 1975; 15: 241-245.
102. Gimbrone MA, Cotran RS, Leapman SB, Folkman J. Tumor growth and neovascularization: an experimental model using the rabbit cornea. J Natl Cancer Inst 1974; 52: 413-427.
103. Bock F, Onderka J, Dietrich T, Bachmann B, Kruse FE, Paschke M et al. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 2007; 48: 2545-2552. (Pubitemid 351261204)
104. Klausner EA, Peer D, Chapman RL, Multack RF, Andurkar SV. Corneal gene therapy J Controlled Release 2007; 124: 107-133. (Pubitemid 350101883)
105. DeStafeno JJ, Kim T. Topical bevacizumab therapy for corneal neovascularization. Arch Ophthalmol 2007; 125: 834-836. (Pubitemid 46919748)
106. Uy HS, Chan PS, Ang RE. Topical bevacizumab and ocular surface neovascularization in patients with stevens-johnson syndrome. Cornea 2008; 27: 70-73.
107. Bock F, König Y, Kruse F, Baier M, Cursiefen C. Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2008; 246: 281-284. (Pubitemid 351149633)
108. Saxena S, Kishore P, Pandey S, Khattri M, Kumar D. Topical bevacizumab for corneal neovascularization after penetrating keratoplasty Eur J Ophthalmol 2009; 19: 870-872.
109. Lim M, Jacobs DS, Rosenthal P, Carrasquillo KG. The Boston Ocular Surface Prosthesis as a novel drug delivery system for bevacizumab. Semin Ophthalmol 2009; 24: 149-155.
110. Koenig Y, Bock F, Horn F, Kruse F, Straub K, Cursiefen C. Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2009; 247(10): 1375-1382.
111. Dastjerdi MH, Al-Arfaj KM, Nallasamy N, Hamrah P, Jurkunas UV, Pineda 2nd R et al. Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study. Arch Ophthalmol 2009; 127: 381-389.
112. Doctor PP, Bhat PV, Foster CS. Subconjunctival bevacizumab for corneal neovascularization. Cornea 2008; 27: 992-995.
113. Bahar I, Kaiserman I, McAllum P, Rootman D, Slomovic A. Subconjunctival bevacizumab injection for corneal neovascularization. Cornea 2008; 27: 142-147. (Pubitemid 351158729)
114. Erdurmus M, Totan Y. Subconjunctival bevacizumab for corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2007; 245: 1577-1579. (Pubitemid 47423342)
115. Zaki AA, Farid SF. Subconjunctival bevacizumab for corneal neovascularization. Acta Ophthalmol 2010; 88: 868-871.
116. Jeong JH, Chun YS, Kim ES, Kim JC. Compensatory growth factor and cytokine response in tears after subconjunctival bevacizumab injection. Cornea 2011; 30: 1071-1077.
117. Vassileva PI, Hergeldzhieva TG. Avastin use in high risk corneal transplantation. Graefes Arch Clin Exp Ophthalmol 2009; 247: 1701-1706.
118. Oh JY, Kim MK, Wee WR. Subconjunctival and intracorneal bevacizumab injection for corneal neovascularization in lipid keratopathy Cornea 2009; 28: 1070-1073.
119. Yeung SN, Lichtinger A, Kim P, Amiran MD, Slomovic AR. Combined use of subconjunctival and intracorneal bevacizumab injection for corneal neovascularization. Cornea 2011; 30: 1110-1114.